Carna Biosciences, Inc. reported consolidated earnings results for the nine months ended September 30, 2019. For the period, the company reported net sales of JPY 2,862 million compared to JPY 586 million a year ago. Operating profit was JPY 1,357 million compared to operating loss of JPY 762 million a year ago. Profit was JPY 1,113.049 million or JPY 104.16 per basic share compared to loss of JPY 822.927 million or JPY 85.82 million a year ago. Diluted earnings per share were JPY 102.07.

The company provided consolidated earnings guidance for the full year ending December 31, 2019. The company expects net sales of JPY 3,038 million, operating profit of JPY 313 million, profit attributable to shareholders of the parent company of JPY 214 million or JPY 20.12 per share.